 Angiotensin II
"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.641.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- Angiotensin-(1-8) Octapeptide
- ANG-(1-8)Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Isoleucyl(5)-Angiotensin II
- Isoleucine(5)-Angiotensin
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- II, 5-L-Isoleucine Angiotensin
- Angiotensin II, Isoleucine(5)-
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in UAMS Profiles by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 | | 2015 | 1 | 2 | 3 | | 2014 | 3 | 1 | 4 | | 2013 | 4 | 0 | 4 | | 2012 | 2 | 3 | 5 | | 2011 | 0 | 1 | 1 | | 2010 | 5 | 2 | 7 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 3 | 4 | | 2007 | 3 | 2 | 5 | | 2006 | 2 | 2 | 4 | | 2005 | 3 | 1 | 4 | | 2004 | 4 | 4 | 8 | | 2003 | 1 | 2 | 3 | | 2002 | 2 | 3 | 5 | | 2001 | 0 | 1 | 1 | | 1998 | 2 | 2 | 4 | | 1997 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles over the past ten years.
-
Pal S, Bagchi AK, Henry DS, Landes RD, Mu S, Rhee SW, Rusch NJ, Stolarz AJ. Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats. Hypertension. 2025 Jan; 82(1):72-83.
-
Althammer F, Roy RK, Kirchner MK, Campos-Lira E, Whitley KE, Davis S, Montanez J, Ferreira-Neto HC, Danh J, Feresin R, Biancardi VC, Zafar U, Parent MB, Stern JE. Angiotensin II-Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats. Hypertension. 2023 06; 80(6):1258-1273.
-
Ozkizilcik A, Sysavanh F, Patel S, Tandon I, Balachandran K. Local Renin-Angiotensin System Signaling Mediates Cellular Function of Aortic Valves. Ann Biomed Eng. 2021 Dec; 49(12):3550-3562.
-
Vackov? ?, Kikerlov? S, Melenovsky V, Kol?r F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney Blood Press Res. 2019; 44(4):792-809.
-
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, S?nchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019 08 02; 20(1):292.
-
Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203.
-
Cervenka L, Huskov? Z, Kopkan L, Kikerlov? S, Sedl?kov? L, Vanourkov? Z, Al?nov? P, Kol?r F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neck?r J. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. J Hypertens. 2018 06; 36(6):1326-1341.
-
Salazar G, Huang J, Feresin RG, Zhao Y, Griendling KK. Zinc regulates Nox1 expression through a NF-?B and mitochondrial ROS dependent mechanism to induce senescence of vascular smooth muscle cells. Free Radic Biol Med. 2017 07; 108:225-235.
-
Stec DE, Juncos LA, Granger JP. Renal intramedullary infusion of tempol normalizes the blood pressure?response to intrarenal blockade of heme oxygenase-1 in?angiotensin II-dependent hypertension. J Am Soc Hypertens. 2016 Apr; 10(4):346-51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|